Japan's Remake of 'Doctor Lawyer' Flips the K-Drama Power Flow

The Reversal That Goes Without Saying

Japan is making a remake of a Korean drama. Not for the first time — Japan has exported far more shows to Korea than vice versa for decades. But the context matters: this time the source material is a Korean show that conquered the world through Netflix, not a Japanese format Japan is testing abroad.

“Doctor Lawyer” (우영우 변호사는 천재肌) premiered in South Korea in 2022 and became something rare — a Korean drama that turned into a genuine global phenomenon. Park Eun-bin’s portrayal of a lawyer on the autism spectrum earned the Grand Prize at the Baeksang Arts Awards, and the series sat at #1 on Netflix’s global non-English TV chart for seven consecutive weeks. It wasn’t just a hit in Asia. It was a hit in Brazil, in France, in places where K-dramas rarely break through.

Now it’s being remade in Japan. Starring Mana Ashida. Airing on Kansai TV and Fuji TV starting October 19, 2026, with simultaneous global streaming on Netflix from the first episode. The title becomes “Minami Minami Bengoshi wa Tensai Hadaka” — Minami Minami, a woman whose palindrome name becomes a gimmick in the source, preserved here with a different character.

What This Tells Us About the Flow of Culture

For most of recent history, the direction was clear: Japan exported manga, anime, and J-drama formats to the rest of Asia. Korea consumed Japanese pop culture voraciously — and paid for it with box office receipts and licensing deals. China did the same. Taiwan, Hong Kong, Thailand all imported Japanese intellectual property and adapted it for local audiences.

Korea was the importer. Japan was the exporter. That hierarchy is dissolving.

“Doctor Lawyer” isn’t Korea’s first globally successful drama — “Parasite” the film showed what was possible in 2019, and “Squid Game” confirmed it in 2021. But those were English-subtitled exceptions that Western media covered as surprises. A Korean drama now being formally remade by Japanese television — a system that historically treated foreign formats as inferior, not as templates to be lifted — carries a different weight.

The reversal is structural, not incidental. Japan’s major networks (Fuji, TBS, NHK) have long maintained domestic format pipelines. They don’t typically look across the sea for proven hits. The fact that they did here suggests the balance of creative authority in East Asia has shifted in a way that many English-language commentators are still not registering.

Why Ashida? Why Now?

Mana Ashida is one of Japan’s most bankable child-turned-adult actresses. She broke out as a teenage sensation and has maintained steady work since. Casting her in her first legal drama signals that the production sees this role as award-worthy, not just rating-friendly. Ashida’s public persona — precise, controlled, emotionally contained — maps unusually well onto a character with ASD.

More interestingly, the production chose to globalize immediately. Instead of a traditional Japanese broadcast window followed by delayed international release, Netflix will stream every episode the moment it airs domestically. This is a deliberate strategy: capture the Korean drama diaspora, pull in fans who discovered the original on Netflix, and let the domestic ratings follow the streaming data rather than the other way around.

It also means Japanese critics and viewers will be compared directly to Park Eun-bin from episode one. That’s high-risk, high-reward casting logic.

Who Wins, Who Loses

Netflix wins most obviously. They own the original. They distribute the remake. They collect the data. Every viewer who watches both versions feeds their recommendation engine, and neither network has to negotiate cross-border rights because Netflix collapsed the geography entirely.

Korean creatives win in a less visible way. The writers, producers, and designers behind “Doctor Lawyer” see their IP recognized as premium enough to remake — not the other way around. Japan’s adaptation retains the core narrative (ASD lawyer, courtroom reversals, family secrets, romantic subplot), which means Korean creative labor is now a foundational layer of a Japanese prime-time show. That didn’t happen twenty years ago.

Japanese broadcasters win too, but conditionally. “Minami Minami” has built-in audience awareness. It’s not a gamble on an untested script — it’s a gamble on whether Ashida can carry the emotional weight that Park Eun-bin carried, and whether Japanese viewers will accept a protagonist whose neurological differences are central rather than incidental.

Japanese network executives who assumed Korean content was only good for streaming niches lose the most. This isn’t a streaming-only play. It’s a Monday 10 p.m. linear drama — the slot where flagship shows live in Japan. If it underperforms, it signals that the K-drama remake model doesn’t translate to linear Japanese television. If it succeeds, it opens a door that has been closed for decades.

What Happens Next

Expect this to be tested repeatedly. If “Minami Minami” performs well domestically and on Netflix, expect more Korean originals to enter the Japanese remake pipeline — not just dramas, but formats, variety shows, perhaps even film remakes. The infrastructure for adaptation already exists in Japan. The question is whether the cultural permission structure will expand fast enough to match the commercial opportunity.

Japan’s television industry has historically been insular. Network in-house production, contracted talent agencies, limited foreign co-productions — the system rewards predictability. A Korean remake entering Monday prime time is a crack in that pattern. Whether it becomes a precedent or stays a one-off depends on what happens after the first three episodes air in October 2026.

The more permanent shift: East Asian audiences are now fluent in each other’s storytelling. A Japanese viewer in 2026 knows who Park Eun-bin is. A Korean viewer knows who Mana Ashida is. The barrier that once made cross-border remakes feel like cultural concessions is gone. What remains is a market where the best story wins — and for the first time in decades, the best story might come from Seoul.